Caredx and collaborators present latest cardiothoracic advancements at the 2024 international society for heart and lung transplantation meeting

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna)- the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that caredx and study collaborators will be presenting the latest data featuring caredx's cardiothoracic portfolio at the international society for heart and lung transplantation (ishlt) 44th.
CDNA Ratings Summary
CDNA Quant Ranking